vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to advancing novel orally administered small molecule therapies targeting significant unmet medical needs, particularly in central nervous system disorders and metabolic diseases. With a diversified pipeline and a management team experienced in drug development, the company is strategically positioned to expedite its therapeutic innovations through key partnerships. vTv Therapeutics is dedicated to driving transformative healthcare solutions that improve patient outcomes while optimizing shareholder value in the dynamic biotechnology landscape. Show more

Location: 3980 PREMIER DRIVE, HIGH POINT, NC, UNITED STATES, 27265, Suite 310, High Point, NC, 27265, USA | Website: https://vtvtherapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

122.1M

52 Wk Range

$14.00 - $44.00

Previous Close

$31.01

Open

$31.11

Volume

26,150

Day Range

$28.84 - $33.04

Enterprise Value

45.24M

Cash

98.5M

Avg Qtr Burn

-5.222M

Insider Ownership

23.60%

Institutional Own.

30.05%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cadisegliatin (TTP399) Details Type 1 diabetes, Diabetes	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HPP737 Details Psoriasis, Skin disease/disorder	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cadisegliatin (TTP399) Details Diabetes, Type 2 diabetes	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.